Evidence map›Paper›PMID 32995791›Full record

ArticlebioRxiv : the preprint server for biology2020

Baseline T cell immune phenotypes predict virologic and disease control upon SARS-CoV infection.

Jessica B Graham, Jessica L Swarts, Sarah R Leist, Alexandra Schäfer, Vineet D Menachery, Lisa E Gralinski, Sophia Jeng, Darla R Miller, Michael A Mooney, Shannon K McWeeney and 5 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Jessica B GrahamVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Jessica L SwartsVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Sarah R LeistDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Alexandra SchäferDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Vineet D MenacheryDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Lisa E GralinskiDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Sophia JengOHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
Darla R MillerDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Michael A MooneyOregon Clinical and Translational Research Institute, Oregon Health & Science University, Portland, OR.
Shannon K McWeeneyOHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
Martin T FerrisDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Fernando Pardo-Manuel de VillenaDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Mark T HeiseDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Ralph S BaricDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Jennifer M LundVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
University of North Carolina at Chapel Hill · USInfectious Disease Research Institute · USOregon Health & Science University · US

Funding

Unlocking Zika Virus Immune Control and Pathogenesis with the Collaborative CrossU19AI100625 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MCWEENEY, SHANNON K. · 2012 to 2021
$36.6M
NIAID NIH HHS U19 AI100625
6 · The paper itself

Abstract

The COVID-19 pandemic has revealed that infection with SARS-CoV-2 can result in a wide range of clinical outcomes in humans, from asymptomatic or mild disease to severe disease that can require mechanical ventilation. An incomplete understanding of immune correlates of protection represents a major barrier to the design of vaccines and therapeutic approaches to prevent infection or limit disease. This deficit is largely due to the lack of prospectively collected, pre-infection samples from indiviuals that go on to become infected with SARS-CoV-2. Here, we utilized data from a screen of genetically diverse mice from the Collaborative Cross (CC) infected with SARS-CoV to determine whether circulating baseline T cell signatures are associated with a lack of viral control and severe disease upon infection. SARS-CoV infection of CC mice results in a variety of viral load trajectories and disease outcomes. Further, early control of virus in the lung correlates with an increased abundance of activated CD4 and CD8 T cells and regulatory T cells prior to infections across strains. A basal propensity of T cells to express IFNg and IL17 over TNFa also correlated with early viral control. Overall, a dysregulated, pro-inflammatory signature of circulating T cells at baseline was associated with severe disease upon infection. While future studies of human samples prior to infection with SARS-CoV-2 are required, our studies in mice with SARS-CoV serve as proof of concept that circulating T cell signatures at baseline can predict clinical and virologic outcomes upon SARS-CoV infection. Identification of basal immune predictors in humans could allow for identification of individuals at highest risk of severe clinical and virologic outcomes upon infection, who may thus most benefit from available clinical interventions to restrict infection and disease. SUMMARY: We used a screen of genetically diverse mice from the Collaborative Cross infected with mouse-adapted SARS-CoV in combination with comprehensive pre-infection immunophenotyping to identify baseline circulating immune correlates of severe virologic and clinical outcomes upon SARS-CoV infection.

Identifiers

PMID32995791
PMCPMC7523117
OpenAlexW3087270518

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.